Design, synthesis, and evaluation of novel diphenyl ether derivatives against drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis

被引:12
作者
Kar, Sidhartha S. [1 ]
Bhat, Varadaraj G. [1 ]
Shenoy, Vishnu P. [2 ]
Bairy, Indira [3 ]
Shenoy, G. Gautham [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut Chem, Manipal, Karnataka, India
[2] Manipal Acad Higher Educ, Dept Microbiol, Kasturba Med Coll, Manipal, Karnataka, India
[3] Manipal Acad Higher Educ, Melaka Manipal Med Coll, Manipal, Karnataka, India
关键词
antitubercular agents; diphenyl ether; human liver microsomal stability; physicochemical studies; safety profile; INHIBITION; TRICLOSAN; GROWTH; SYSTEM; ASSAY; FABI;
D O I
10.1111/cbdd.13379
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In our efforts to develop druggable diphenyl ethers as potential antitubercular agents, a series of novel diphenyl ether derivatives (5a-f, 6a-f) were designed and synthesized. The representative compounds showed promising in vitro activity against drug-susceptible, isoniazid-resistant, and multidrug-resistant strains of Mycobacterium tuberculosis with MIC values of 1.56 mu g/ml (6b), 6.25 mu g/ml (6a-d), and 3.125 mu g/ml (6b-c), respectively. All the synthesized compounds exhibited satisfactory safety profile (CC50 > 300 mu g/ml) against Vero and HepG2 cells. Reverse phase HPLC method was used to probe the physicochemical properties of the synthesized compounds. This series of compounds demonstrated comparatively low logP values. pKa values of representative compounds indicated that they were weak acids. Additionally, in vitro human liver microsomal stability assay confirmed that the synthesized compounds possessed acceptable stability under study conditions. The present study thus establishes compound 6b as the most promising antitubercular agent with acceptable drug-likeness.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 20 条
[1]   Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis [J].
Ådjers-Koskela, K ;
Katila, ML .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (03) :1235-1239
[2]   Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium [J].
Collins, LA ;
Franzblau, SG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1004-1009
[3]   A route to the structure proposed for puetuberosanol and approaches to the natural products marshrin and phebalosin [J].
Gillmore, A ;
Lauret, C ;
Roberts, SM .
TETRAHEDRON, 2003, 59 (24) :4363-4375
[4]   Resistance in tuberculosis: what do we know and where can we go? [J].
Green, Keith D. ;
Garneau-Tsodikova, Sylvie .
FRONTIERS IN MICROBIOLOGY, 2013, 4
[5]   Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis [J].
Heath, RJ ;
Yu, YT ;
Shapiro, MA ;
Olson, E ;
Rock, CO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (46) :30316-30320
[6]  
Hijova E, 2006, Bratisl Lek Listy, V107, P80
[7]   Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents [J].
Kar, Sidhartha S. ;
Bhat, Varadaraj ;
Rao, Praveen P. N. ;
Shenoy, Vishnu P. ;
Bairy, Indira ;
Shenoy, G. Gautham .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :2299-2310
[8]  
Li P., 2008, J CHIN CHEM SOC-TAIP, V55, P390
[9]   ElogPoct:: A tool for lipophilicity determination in drug discovery [J].
Lombardo, F ;
Shalaeva, MY ;
Tupper, KA ;
Gao, F ;
Abraham, MH .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2922-2928
[10]   Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I [J].
McLeod, R ;
Muench, SP ;
Rafferty, JB ;
Kyle, DE ;
Mui, EJ ;
Kirisits, MJ ;
Mack, DG ;
Roberts, CW ;
Samuel, BU ;
Lyons, RE ;
Dorris, M ;
Milhous, WK ;
Rice, DW .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2001, 31 (02) :109-113